A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone

Genentech

Status: Completed

Conditions: Turner Syndrome

Study type: Observational

Funder types: Industry

Identifiers

NCT00097552

85-036, Substudy 9

Details and patient eligibility

About

This study is a multicenter, open-label, observational, postmarketing surveillance study of Genentech growth hormone (GH) products in the treatment of girls with Turner syndrome in the United States and Canada.

Enrollment: 1,696 patients

Sex: Female

Ages: Under 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Are girls with Turner syndrome who are being or will be treated with Nutropin, Nutropin AQ, or Protropin
• Are willing to keep follow-up appointments throughout study participation
• Are girls with Turner syndrome who have submitted Form 4 upon discontinuation and may also submit Form 9

Exclusion criteria

• Have Noonan syndrome
• Subjects treated within the last 6 months with a non-Genentech GH preparation
• Have closed epiphyses prior to NCGS enrollment
• Have active neoplasia